Gemfibrozil Tablet
Product Images NDC 71335-1996

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 71335-1996). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Additional Adverse Reactions (Additional Adv Drug Reactions)

This is a list of potential side effects and symptoms that could occur from using a certain medication. The text does not specify which medication it is referring to. Some of the reported symptoms include weight loss, heart arrhythmias, gastrointestinal issues, confusion, vision problems, muscle pain, and liver dysfunction. The text also mentions potential effects on the immune system and skin. Caution should be taken when using this medication and patients should be monitored closely for any adverse reactions.*

FDA Label Image

Adverse Reactions (Adv Reactions)

This text reports adverse reactions to Gemfibrozil compared to a placebo in a clinical trial. It includes the frequency of gastrointestinal reactions, dyspepsia, abdominal pain, acute appendicitis, and atrial fibrillation. Additionally, it lists adverse events reported by over 1% of subjects, including diarrhea, fatigue, nausea/vomiting, eczema, rash, vertigo, constipation, and headache, with no significant difference between the two groups.*

FDA Label Image

Struct (Structure Gemfibrozil)

FDA Label Image

Table1 (Table 1)

This is a table showing the reduction in coronary heart disease rates in patients with various baseline lipid levels in the Helsinki Heart Study over 5 years. It includes the number of events per 1000 patients, the incidence of events, and the difference in rates between the placebo and gemfibrozil groups. The lipids measured at baseline are LDL-C, HDL-C, and TG.*

FDA Label Image

Table2 (Table 2)

The table shows cardiac events and all-cause mortality rates (per 1000 patients) during the 3.5 year open-label follow-up to the Helsinki Heart Study. The groups are classified by PDrop, PN, PG, GDrop, GN, and GG, with varying numbers of patients in each group. The cardiac events and all-cause mortality rates are provided for each group. The groups are also described according to the original randomization, placebo, and gemfibrozil, and the attendance at the clinic and drug taken during follow-up.*

FDA Label Image

Table3 (Table 3)

The table provides information on cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality in the Helsinki Heart Study over a period of 8.5 years, comparing the effects of Gemfibrozil and Placebo. It includes hazard ratios for each event, indicating the risk for the group originally randomized for Gemfibrozil compared to the placebo group. The analysis includes the originally randomized patients without considering open-label treatment.*

FDA Label Image

Label (Lbl713351996)

This is a medication label for a 600mg tablet of Gemfibrozil. It is oval and white in color. The label provides instructions to store at room temperature, keep away from children, and warns against the use of expired medication. The drug is manufactured by Scent Pharmaceuticals, Inc. The label also includes the National Drug Code (NDC) and an expiration date.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.